Financhill
Sell
15

ALLK Quote, Financials, Valuation and Earnings

Last price:
$0.26
Seasonality move :
-9.89%
Day range:
$0.25 - $0.26
52-week range:
$0.23 - $1.56
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.29x
Volume:
451K
Avg. volume:
1.5M
1-year change:
-80.62%
Market cap:
$22.9M
Revenue:
--
EPS (TTM):
-$1.32

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ALLK
Allakos
-- -$0.18 -- -62.96% $0.35
AKRO
Akero Therapeutics
-- -$1.12 -- -16.23% $77.64
BIIB
Biogen
$2.4B $3.36 -1.89% 33.96% $201.18
NBY
NovaBay Pharmaceuticals
$2.5M -$0.24 14.03% -95.43% $0.85
SAGE
Sage Therapeutics
$14.4M -$1.36 79.76% -43.33% $8.05
VNDA
Vanda Pharmaceuticals
$52.3M -- -4.9% -- $12.67
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ALLK
Allakos
$0.25 $0.35 $22.9M -- $0.00 0% --
AKRO
Akero Therapeutics
$44.88 $77.64 $3.6B -- $0.00 0% --
BIIB
Biogen
$143.54 $201.18 $21B 12.83x $0.00 0% 2.17x
NBY
NovaBay Pharmaceuticals
$0.64 $0.85 $3.1M -- $0.00 0% 0.07x
SAGE
Sage Therapeutics
$8.02 $8.05 $493.1M -- $0.00 0% 11.82x
VNDA
Vanda Pharmaceuticals
$5.08 $12.67 $296.2M -- $0.00 0% 1.49x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ALLK
Allakos
-- -4.402 -- --
AKRO
Akero Therapeutics
-- 3.401 -- --
BIIB
Biogen
27.36% 0.257 28.25% 0.77x
NBY
NovaBay Pharmaceuticals
4.54% 0.646 1.51% 0.75x
SAGE
Sage Therapeutics
-- 0.494 -- 7.17x
VNDA
Vanda Pharmaceuticals
-- -0.270 -- 4.22x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ALLK
Allakos
-- -$24.7M -- -- -- -$12.5M
AKRO
Akero Therapeutics
-- -$78M -- -- -- -$67.1M
BIIB
Biogen
$1.9B $450.6M 7.33% 10.33% 14.32% $694.6M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
SAGE
Sage Therapeutics
$11.3M -$80.3M -63.59% -63.59% -626.87% -$66.6M
VNDA
Vanda Pharmaceuticals
$50.6M -$10.3M -3.49% -3.49% -19.33% -$2M

Allakos vs. Competitors

  • Which has Higher Returns ALLK or AKRO?

    Akero Therapeutics has a net margin of -- compared to Allakos's net margin of --. Allakos's return on equity of -- beat Akero Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ALLK
    Allakos
    -- -- --
    AKRO
    Akero Therapeutics
    -- -$0.99 --
  • What do Analysts Say About ALLK or AKRO?

    Allakos has a consensus price target of $0.35, signalling upside risk potential of 37.85%. On the other hand Akero Therapeutics has an analysts' consensus of $77.64 which suggests that it could grow by 72.99%. Given that Akero Therapeutics has higher upside potential than Allakos, analysts believe Akero Therapeutics is more attractive than Allakos.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALLK
    Allakos
    0 7 0
    AKRO
    Akero Therapeutics
    9 0 0
  • Is ALLK or AKRO More Risky?

    Allakos has a beta of 0.719, which suggesting that the stock is 28.106% less volatile than S&P 500. In comparison Akero Therapeutics has a beta of -0.193, suggesting its less volatile than the S&P 500 by 119.294%.

  • Which is a Better Dividend Stock ALLK or AKRO?

    Allakos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allakos pays -- of its earnings as a dividend. Akero Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ALLK or AKRO?

    Allakos quarterly revenues are --, which are smaller than Akero Therapeutics quarterly revenues of --. Allakos's net income of $376K is higher than Akero Therapeutics's net income of -$70M. Notably, Allakos's price-to-earnings ratio is -- while Akero Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allakos is -- versus -- for Akero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALLK
    Allakos
    -- -- -- $376K
    AKRO
    Akero Therapeutics
    -- -- -- -$70M
  • Which has Higher Returns ALLK or BIIB?

    Biogen has a net margin of -- compared to Allakos's net margin of 10.87%. Allakos's return on equity of -- beat Biogen's return on equity of 10.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALLK
    Allakos
    -- -- --
    BIIB
    Biogen
    76.23% $1.83 $23B
  • What do Analysts Say About ALLK or BIIB?

    Allakos has a consensus price target of $0.35, signalling upside risk potential of 37.85%. On the other hand Biogen has an analysts' consensus of $201.18 which suggests that it could grow by 40.16%. Given that Biogen has higher upside potential than Allakos, analysts believe Biogen is more attractive than Allakos.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALLK
    Allakos
    0 7 0
    BIIB
    Biogen
    13 17 0
  • Is ALLK or BIIB More Risky?

    Allakos has a beta of 0.719, which suggesting that the stock is 28.106% less volatile than S&P 500. In comparison Biogen has a beta of 0.012, suggesting its less volatile than the S&P 500 by 98.773%.

  • Which is a Better Dividend Stock ALLK or BIIB?

    Allakos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allakos pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ALLK or BIIB?

    Allakos quarterly revenues are --, which are smaller than Biogen quarterly revenues of $2.5B. Allakos's net income of $376K is lower than Biogen's net income of $266.7M. Notably, Allakos's price-to-earnings ratio is -- while Biogen's PE ratio is 12.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allakos is -- versus 2.17x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALLK
    Allakos
    -- -- -- $376K
    BIIB
    Biogen
    2.17x 12.83x $2.5B $266.7M
  • Which has Higher Returns ALLK or NBY?

    NovaBay Pharmaceuticals has a net margin of -- compared to Allakos's net margin of -49.65%. Allakos's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALLK
    Allakos
    -- -- --
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About ALLK or NBY?

    Allakos has a consensus price target of $0.35, signalling upside risk potential of 37.85%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.89%. Given that Allakos has higher upside potential than NovaBay Pharmaceuticals, analysts believe Allakos is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALLK
    Allakos
    0 7 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is ALLK or NBY More Risky?

    Allakos has a beta of 0.719, which suggesting that the stock is 28.106% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.

  • Which is a Better Dividend Stock ALLK or NBY?

    Allakos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allakos pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ALLK or NBY?

    Allakos quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Allakos's net income of $376K is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Allakos's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allakos is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALLK
    Allakos
    -- -- -- $376K
    NBY
    NovaBay Pharmaceuticals
    0.07x -- $2.4M -$1.2M
  • Which has Higher Returns ALLK or SAGE?

    Sage Therapeutics has a net margin of -- compared to Allakos's net margin of -747.33%. Allakos's return on equity of -- beat Sage Therapeutics's return on equity of -63.59%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALLK
    Allakos
    -- -- --
    SAGE
    Sage Therapeutics
    88.38% -$1.56 $465.1M
  • What do Analysts Say About ALLK or SAGE?

    Allakos has a consensus price target of $0.35, signalling upside risk potential of 37.85%. On the other hand Sage Therapeutics has an analysts' consensus of $8.05 which suggests that it could grow by 0.33%. Given that Allakos has higher upside potential than Sage Therapeutics, analysts believe Allakos is more attractive than Sage Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALLK
    Allakos
    0 7 0
    SAGE
    Sage Therapeutics
    0 15 0
  • Is ALLK or SAGE More Risky?

    Allakos has a beta of 0.719, which suggesting that the stock is 28.106% less volatile than S&P 500. In comparison Sage Therapeutics has a beta of 0.817, suggesting its less volatile than the S&P 500 by 18.337%.

  • Which is a Better Dividend Stock ALLK or SAGE?

    Allakos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sage Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allakos pays -- of its earnings as a dividend. Sage Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ALLK or SAGE?

    Allakos quarterly revenues are --, which are smaller than Sage Therapeutics quarterly revenues of $12.8M. Allakos's net income of $376K is higher than Sage Therapeutics's net income of -$95.8M. Notably, Allakos's price-to-earnings ratio is -- while Sage Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allakos is -- versus 11.82x for Sage Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALLK
    Allakos
    -- -- -- $376K
    SAGE
    Sage Therapeutics
    11.82x -- $12.8M -$95.8M
  • Which has Higher Returns ALLK or VNDA?

    Vanda Pharmaceuticals has a net margin of -- compared to Allakos's net margin of -9.24%. Allakos's return on equity of -- beat Vanda Pharmaceuticals's return on equity of -3.49%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALLK
    Allakos
    -- -- --
    VNDA
    Vanda Pharmaceuticals
    95.13% -$0.08 $538.5M
  • What do Analysts Say About ALLK or VNDA?

    Allakos has a consensus price target of $0.35, signalling upside risk potential of 37.85%. On the other hand Vanda Pharmaceuticals has an analysts' consensus of $12.67 which suggests that it could grow by 149.34%. Given that Vanda Pharmaceuticals has higher upside potential than Allakos, analysts believe Vanda Pharmaceuticals is more attractive than Allakos.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALLK
    Allakos
    0 7 0
    VNDA
    Vanda Pharmaceuticals
    1 1 0
  • Is ALLK or VNDA More Risky?

    Allakos has a beta of 0.719, which suggesting that the stock is 28.106% less volatile than S&P 500. In comparison Vanda Pharmaceuticals has a beta of 0.689, suggesting its less volatile than the S&P 500 by 31.079%.

  • Which is a Better Dividend Stock ALLK or VNDA?

    Allakos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allakos pays -- of its earnings as a dividend. Vanda Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ALLK or VNDA?

    Allakos quarterly revenues are --, which are smaller than Vanda Pharmaceuticals quarterly revenues of $53.2M. Allakos's net income of $376K is higher than Vanda Pharmaceuticals's net income of -$4.9M. Notably, Allakos's price-to-earnings ratio is -- while Vanda Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allakos is -- versus 1.49x for Vanda Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALLK
    Allakos
    -- -- -- $376K
    VNDA
    Vanda Pharmaceuticals
    1.49x -- $53.2M -$4.9M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is CyberArk The Next Big Cybersecurity Stock?
Is CyberArk The Next Big Cybersecurity Stock?

CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
52
RGC alert for Mar 18

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Buy
63
EXOD alert for Mar 18

Exodus Movement [EXOD] is down 3.96% over the past day.

Sell
45
MNPR alert for Mar 18

Monopar Therapeutics [MNPR] is up 0.93% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock